• CNSC partners with InvestorBrandNetwork to maximize communication, refine messaging and outreach.
• CannAssist focused on marketing Xceptol consumer brand, which provides products featuring proprietary CiBiDinol technology.
• IBN brings 15-plus years of experience assisting more than 500 client partners improve communications within investment community.

Recognizing the critical nature of communications to the success of a business, CannAssist International (OTCQB: CNSC) has selected to partner with InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities (https://ibn.fm/o1Oav). CannAssist, a biotechnological pharmaceutical and wellness company, owns Xceptor Labs, an R&D and raw material manufacturer, which also has its own product line. “We are pleased to engage IBN to maximize our communication with existing and potential shareholders while refining our overall messaging and outreach,” said CannAssist CEO Mark Palumbo. Currently, CannAssist is focused on marketing its Xceptol consumer brand, which provides products that feature Xceptor Labs’ proprietary CiBiDinol technology. According to CannAssist, CiBiDinol is a method of creating CBD products that have better absorption than other oil-based products currently available. CiBiDinol provides CBD in a format that is more in line with the body’s natural bioactivity, the company said. Specifically, CiBiDinol is designed to tackle issues with oil-soluble CBD molecules, such as delivery, bioavailability and short shelf-life. CannAssist notes that the product in the brand also offers more predictable potency. The CannAssist story is certainly one worth telling, and IBN is focused on telling that story through a variety of ways. IBN has built an investor-based distribution network of 5,000-plus key syndication outlets; the company also produces various newsletters and manages a variety of social media platforms, wire service, blogs and other outreach tools. The purpose of the IBN partnership is to generate greater awareness for CannAssist International Corp. “The cannabidiol market has been on fire since the 2018 Farm Bill was signed into law,” said IBN director of client solutions Chris Johnson. “In 2018, the global CBD market was valued at $4.6 billion, and it’s forecast to reach $23.6 billion by 2025, according to Grand View Research. CannAssist is uniquely positioned to capitalize on this market growth. “Based on current revenue from raw material sales, retail sales and the Xceptol brand’s international distribution, CannAssist expects to reach first-year sales of $5 million,” Johnson continued. “We’re excited to customize our comprehensive suite of corporate communications solutions for the company as it seeks to expand its product pipeline and achieve steady sales growth in the years ahead.” Johnson noted that with 15-plus years of experience assisting more than 500 client partners improve communications within the investment community, IBN is the ideal organization to work alongside CannAssist. Through its family of 50-plus trusted brands and millions of social media followers, IBN is uniquely positioned to offer CannAssist the essential expertise, insight and tools to reach a wider audience of investors, consumers and more. CannAssist, owner of Xceptor Labs, is a biotechnological pharmaceutical and wellness company. Established in May 2017, CannAssist is headquartered in San Diego County, California, and markets its consumer line of cannabidiol (“CBD”) products under the Xceptol brand. For more information, visit the company’s website at www.CannAssistInternational.com. NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://ibn.fm/CNSC

• POAI sent letter to shareholders requesting attendance at virtual Special Meeting on December 30, 2020
• Meeting will address reincorporation of POAI in Nevada
• Reincorporation expected to save POAI approximately $158,000 annually in state taxes
• Shareholders can vote online or by telephone, detailed instructions outlined in proxy materials

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently sent a letter to all shareholders urging them to attend a virtual Special Meeting of Stockholders (the “Meeting”). Originally scheduled for December 1, 2020, the Meeting will be reconvened on December 30, 2020 at 3:00 p.m. CST, where all shareholders will be requested by the Board of Directors and management of POAI to vote “FOR” the proposals put forward at the Meeting. The Board of Directors and management of POAI are proposing that the corporation reincorporates in Nevada for the purpose of eliminating its obligation to pay the Delaware franchise tax of approximately $170,000 per year. By reincorporating in Nevada, POAI management believes that the company can save approximately $158,000 annually in state taxes. “We are asking you to vote for allowing the company to reincorporate in the state of Nevada, moving away from Delaware,” writes POAI CEO Carl Schwartz (https://ibn.fm/UsMtz).  “First and foremost, the reincorporation in Nevada will eliminate our obligation to pay the injurious annual Delaware franchise tax, which is currently equal to approximately $170,000 per year. We can save approximately $158,000 annually in state taxes by reincorporating in Nevada. Also, we believe that for the reasons described in the proxy materials, in general, Nevada law provides greater protection to our directors, officers and the company than Delaware law.” In order for the reincorporation to be approved, the proposal must receive a “For” vote from the majority of outstanding shares of common stock of the company. At POAI’s recent Annual Meeting, the reincorporation vote received a larger amount of “For” votes than “Against” votes; however, the amount required for the vote to pass fell short for a majority of the outstanding shares. Management at POAI is urging all shareholders to vote their shares online or by telephone by following the instructions outlined in their proxy materials. POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow. For more information, visit the company’s website at www.Predictive-Oncology.com. NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Pure Extracts is working with Dr. Alexander MacGregor on development of mushroom products, including some combined with CBD.
• MacGregor is widely renowned as pharmaceutical science inventor, expert in pharmaceutical technology and novel drug-delivery systems.
• Pure Extracts is focused on expansion of its cannabis extraction business model to include mushroom formulations.

Pure Extracts Technologies (CSE: PULL) has established a key collaborative relationship with an expert in translating pharmaceutical knowledge into a sustainable business. The plant-based extraction company, which is focused on cannabis, hemp and the rapidly emerging functional mushroom sector, is working closely with Dr. Alexander MacGregor on developing quality cannabis and mushroom formulations (https://ibn.fm/lkN19). Calling MacGregor a “key scientific advisor,” Pure Extracts announced that it is working with the pharmaceutical and biopharmaceutical expert on the development of CBD-infused mushroom wellness products as well as on researching psilocybin extraction methodologies. These efforts are focused on planning for Pure Extracts’ successful entrance into the psychedelic mushroom extraction space. MacGregor serves as the dean of faculty, distinguished professor of biopharmaceutics and current president of the Toronto Institute of Pharmaceutical Technology (“TIPT”). TIPT is North America’s premier post-graduate institute of pharmaceutical sciences, technology and research. In addition, MacGregor is the CEO of TIPT’s parent company, Transpharm Canada Inc. Transpharm Canada has received a Health Canada Drug Establishment License, a Cannabis Drug License and a Dealer’s License issued under the Controlled Drugs and Substances Act (“CDSA”). Licensed to possess psychedelic drug compounds, Transpharm Canada has extensive expertise in conducting cannabis testing, clinical trials and drug development. MacGregor is widely renowned as a pharmaceutical science inventor and an expert in pharmaceutical technology and novel drug-delivery systems; he is also the holder of several global patents in the field of medical treatments and pharmaceutical drug delivery technologies. His inventions have been key in the discovery of groundbreaking therapeutic drugs for the management of diabetes and the treatment of cancer, systemic infections and post-operative pain. MacGregor has served as a consultant to several multinational pharmaceutical companies, including GlaxoSmithKline, Valeant, Teva, Patheon, Sun Pharma and Beijing Double-Crane Pharma. Pure Extracts is focused on the expansion of its business model to include mushroom formulations through the use of extraction processes that have proven compatible with its existing infrastructure (https://ibn.fm/7sbDz). The company is looking to leverage its expertise to develop high bio-available products and novel delivery methodologies including pills, capsules and edibles. Pure Extracts is also eyeing the opportunity to become a significant extraction partner for the commercialization of new functional mushroom products. In fact, the company has already taken steps in that direction; the Company recently signed a letter of intent with PURICA(TM), one of Canada’s leading functional mushroom wellness brands, to partner together to produce CBD-enhanced mushroom products. Headquartered in Pemberton, British Columbia, Pure Extracts is a plant-based extraction company that appears ideally positioned to be the dominant extraction company in the rapid development and commercialization of novel functional mushroom products. For more information, visit the company’s website at www.PureExtractsCorp.com. NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• New initiative supports artists in promoting, growing, monetizing their fan base.
• FDBL’s new offering focused on fan development and growth.
• CEO believes “artists at every level need what Fan Pass has to offer.”

Friendable (OTC: FDBL) has rolled out a powerful marketing initiative aimed to support performing artists on its Fan Pass live-streaming platform to promote, grow and monetize their fan base (https://ibn.fm/dVLls). The initiative — the only offering focused on fan development and growth — is intended to promote live-stream performances and exclusive content creation on FDBL’s Fan Pass and provide immediate compensation for artists. “Our vision has remained sound as we believe that artists at every level need what Fan Pass has to offer,” said Friendable CEO Robert A. Rositano Jr. “It is our ultimate goal to assist every artist in building and earning with regularity and consistency. Our new marketing initiative provides the attention grab and the follow through to show each artist how our unique approach, tools and offering will help them succeed. It’s amazing to me to see our business model connect and convert on every level as these metrics and small victories being achieved as a startup in a multibillion-dollar marketplace are the milestones and validation we have been seeking as we set our sights on our 2021 capital raise for scale and growth,” An app that is “all about the fans,” FDBL’s Fan Pass connects fans with their favorite artists. Through exclusive VIP offerings, fans can enjoy experiences they might otherwise never be able to afford or geographically attend — right from their smartphones or other connected devices. And fans aren’t the only ones to benefit from the exclusive service. Fan Pass has developed a platform that embraces participating artists with a unique and full-circle approach that builds fan engagement and audience participation and provides substantial earning potential that builds every month. Recently Fan Pass marked a significant milestone as it launched 50 Exclusive Live Artist Channels Across a variety of genes, adding to the overall total of 70 live artist channels (https://ibn.fm/ydgBt). New artist sign-ups bring almost 500,000 fans and followers to the platform. Friendable is a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications. With Fan Pass, artists can offer exclusive content channels to their fans, who can simply use their smartphones to gain access to their favorite artists as well as all-access passes that provide access to all artists on the platform. Additionally, the Fan Pass team will deploy social broadcasters to capture exclusive VIP experiences, interviews and behind-the-scenes content featuring their favorite artists. For more information, visit the company’s website at www.Friendable.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Clean Power Capital Corp. (formerly known as Organic Flower Investments Group Inc.) is a British Columbia-based holding company with investments in a variety of sectors and a growing interest in the U.S. marketplace
• The company recently announced the formation of a strategic committee to examine possibilities for building its investor profile in the United States, including the merits of a potential application to trade its common shares on the NASDAQ exchange
• Clean Power Capital invested in 90 percent of U.S. company PowerTap Hydrogen Fueling this year as part of its drive to grow its investments in the health and renewable energy industries
• PowerTap is currently beginning to build what it hopes will become a 500-strong hydrogen refueling station network across California employing PowerTap’s modular IP
• The state of California, which boasts the world’s fifth-largest economy, is supporting the development of alternative fuels such as hydrogen through financial incentives, helping to drive market researchers at McKinsey & Company’s forecasts that hydrogen could generate $140 billion in annual revenue by 2030

Investment holding company Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF), whose corporate purpose is to help a select set of private and public companies grow to meet their potential, particularly in the health and renewable energy industries, announced recently Dec. 3 that the company is considering the potential benefits of uplisting to the NASDAQ as part of a strategic effort to improve its investor profile in the United States. Clean Power Capital, based on Canada’s western seaboard, has 10 investments in a variety of sectors and successfully held nearly C$120 million in investments during the past fiscal year. Earlier this year, it invested in PowerTap Hydrogen Fueling, a company that employs its IP in fueling stations in California, Texas, Massachusetts, and Maryland and the company. Its current focus is on using its onsite steam methane reforming (“SMR”) hydrogen production and dispensing modular units to build a strong network of at least 500 hydrogen fuel stations throughout California and then to expand across the United States in a phased development approach. Clean Power’s strategic committee will review and develop a new capital markets strategy focused on the United States, according to the company’s announcement. The possibility of listing common shares on the NASDAQ exchange is subject to a number of regulatory and listing requirements, and the company will seek the assistance of a financial adviser to assess the opportunity potential a NASDAQ listing might bring if NASDAQ were to grant a Clean Power application. CEO Joel Dumaresq stated a NASDAQ uplisting seems like a “natural next step” as part of the company’s efforts to generate maximum returns from its investments because of the increased visibility and opportunities to draw new investors an uplisting is expected to provide, and the increased liquidity of the company’s shares as a result. The technology-developing company continues to maintain the listing of its common shares on the Canadian Securities Exchange under the symbol “MOVE.” It is not establishing a deadline for the strategic committee’s review of Clean Power’s capital markets strategy. Clean Power’s equity investment in PowerTap is helping that company to roll out a third-generation improvement of its onsite hydrogen production and dispensing technology for hydrogen trucks and cars in the United States. PowerTap believes it has a market advantage because of the characteristics of its technology’s modular design, which allow it to be assembled and tested prior to delivery. This further simplifies the installation of the technology at already operating sites where suitable zoning permits for the technology are in place, allowing the company a comparatively rapid response to setup and inspection needs (https://ibn.fm/ZAME8). The modular design allows the station technology to be mass produced, to be easily upgraded with new tech developments, and to be relocated if necessary, PowerTap states. Hydrogen fuel is one of the go-to solutions pursued by governments such as California’s in an effort to reduce the world’s dependence on fossil fuels amid concerns about pollutants’ adverse impacts on the global climate. The state, with one of the world’s largest economies, is providing significant financial incentives to help the fuel alternative develop and stations are increasing in number and size as a result (https://ibn.fm/dhzbi). Clean Power’s focus on health and renewable energy industries is tapping into the swelling worldwide concern about the climate and people’s wellness in general (https://ibn.fm/2MC52), exemplified by global accords on the climate in Europe and Asia’s heavy investment in energy alternatives (https://ibn.fm/qsmM7). Market researchers at McKinsey & Company recently predicted that the hydrogen economy could meet 14 percent of total American energy demand by 2050, generating $140 billion in annual revenue by 2030 (https://ibn.fm/KojE1). For more information, visit the company’s website at www.CleanPower.Capital. NOTE TO INVESTORS: The latest news and updates relating to MOTNF are available in the company’s newsroom at https://ibn.fm/MOTNF

• United Medical Equipment focuses on the needs of aging patients and veteran communities, as well as those impacted by the COVID-19 pandemic.
• The company is a trusted supplier of FDA-approved COVID-19 rapid antibody test kits and personal protective equipment (“PPE”) offering flexible payment terms.
• United Medical Equipment is led by a team of professionals who have over 25 years of combined experience in business, 10 years in nursing and over 20 years in sales, marketing and branding.
• By 2026, the global medical supplies industry is projected to reach $95.04 billion, up from $80 billion in 2019, reflecting a CAGR of 13.5%.
• Grand View Research estimates the global COVID-19 diagnostics market at $84.4 billion in 2020.

United Medical Equipment Business Solutions Network is a provider of reliable resources and solutions to fit the ever-changing needs of an aging population that includes seniors and veterans, as well as those impacted by the COVID-19 pandemic. Uniquely poised to offer health care across the continuum of care, United Medical Equipment has solutions that help providers work more proficiently, health care systems work smarter, and patients live healthier lives. The company aims to provide the information, technology and proper equipment needed to maintain safety and health among seniors, veterans, health care workers and other patients. With a corporate office located in Fort Worth, Texas, United Medical Equipment Business Solutions Network operates nationwide. Services United Medical Equipment provides services that have been thoroughly vetted, have a good reputation, and offer the proper resources to care for the aging population and veterans. The company has also moved quickly to address the unique testing needs created by the ongoing COVID-19 pandemic. Services provided by the company include:

• Acting as a trusted senior referral source for independent living, assisted living, hospice, memory care, skilled nursing and senior care centers;
• Serving as a trusted supplier of FDA-approved COVID-19 rapid antibody test kits, with FDA approval for its rapid antigen tests coming soon;
• Serving as a trusted supplier of all personal protective equipment (“PPE”) while offering flexible payment terms and a catalog of roughly 20,000 medical equipment and supply options;
• Offering the Medication Managementapp, which is currently available on the Apple App Store and Google Play and features 11 unique functionalities; and
• Providing comprehensive telehealth solutions through UME Telehealth.

United Medical Equipment Experience and Outlook United Medical Equipment’s owners and founders have decades of combined business experience. With an understanding of the aging population, veterans and their families, they allow the company to offer the support, solutions and reliable information needed to make sometimes difficult but necessary life decisions. In 2019, the worldwide medical supplies market was estimated at $80 billion. This market is expected to grow at a CAGR of 13.5% through 2026, resulting in a projected market size of $95.04 billion (https://ibn.fm/tue4s). Likewise, Grand View Research estimates the global COVID-19 diagnostics market at $84.4 billion in 2020 and forecasts a 3.1% CAGR from 2021 to 2027 (https://ibn.fm/TKBXm). A Global Health and Aging Report presented by the World Health Organization (“WHO”) estimates that, by 2030, more than 60% of individuals over 60 will be managing more than one chronic condition, such as cancer, dementia, increase in falls, diabetes and obesity. This illustrates an ever-greater need for proper placement and resources to care for this aging community, as well as veterans and individuals impacted by the COVID-19 pandemic. United Medical Equipment is committed to addressing this demand. Management Team Jason Pratt is the President, Co-Founder and Structural Architect of United Medical Equipment. He brings 25+ years of multi-faceted business background to the company, accompanied by real-world experience. He is also the President of three other companies, which he also founded. While Pratt served as Regional Director for a home health care company, he saw the need for a reliable senior referral source to provide affordable and targeted solutions. Lesley Hauck, MSN, RN, is the Co-Founder, Secretary, Treasurer and Director of Nurses for United Medical Equipment. She brings over 10 years of knowledge and experience to the company as a cardiovascular critical care nurse and nursing supervisor. Hauck earned her Master of Science in Nursing with an emphasis on clinical systems leadership from the University of Arizona. She has also spent 30 years as the spouse of a career military officer. She has served on many non-profit boards in support of children, veterans and wounded American soldiers. She understands veterans and the needs of their families. Karissa Kaminski is the Director of Operations for United Medical Equipment. She has over 20 years of sales and marketing experience, with a focus on brand management, emphasizing customer satisfaction and operational structures. Her background includes six years in the legal field, including family law, defense, probate and civil litigation. Bob Bounds is the Director of Marketing and Development for United Medical Equipment. He has a background in media marketing and started his career in broadcasting as a cameraman and video editor. Bounds’ career then progressed to producer and director at KTVT-Channel 11 in Dallas-Fort Worth. Bounds has experience in print, broadcast, direct mail and digital marketing strategies. Brock Bradshaw is the Director of Application Design and Development for United Medical Equipment. He is an experienced IT professional with a strong background in enterprise-level software design, development, testing and customer support. He graduated from the University of Texas at Dallas in May 2001 with a Bachelor of Science Degree in Computer Science. Bradshaw’s previous roles include positions at Texas Instruments Inc. and Computer Associates Inc. Brian Gartland is United Medical Equipment’s VP of Sales. Born and raised in the Midwest, Gartland started his career in marketing and entertainment in Columbus, Ohio, as an event planner and concert promoter. Gartland has since spent over a decade in the entertainment field, working for 20th Century Fox and Sony Pictures as a seasoned executive. He has since become extremely knowledgeable with COVID-19 testing and currently works with the company to deliver its clients the best possible COVID solutions for their businesses. For more information, visit the company’s website at www.UnitedMedSolutions.com. NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed

• Knightscope is a private industry security robot developer pioneering autonomous solutions to many long-standing concerns with corporate facility protection
• These robots’ ability to perform repetitive, often boring and sometimes dangerous tasks makes them ideally suited for property patrolling, and their capacity for analyzing and recording their interactions qualifies them for actual crime prevention and reporting
• Knightscope’s models include stationary, indoor mobile and outdoor mobile machines that are outfitted with technological features including 360-degree eye-level HD streaming video, face and license plate recognition, and infrared thermal detection
• Sales promotion of the K5 has showcased its competitiveness by presenting its profile in a curriculum vitae (CV) resume format highlighting its history, achievements and personality
• While Knightscope is not listed on a public exchange, its shares are available for purchase through its Reg A+ offering and the company now boasts more than 17,000 investors that include law enforcement and private security officers experienced in the industry

Autonomous security robot developer Knightscope has built a fleet of security professionals from the ground up to meet the personnel and property protection needs of corporate America in the modern era. Much of the media discussion about security these days appears to focus on cybersecurity concerns, but physical security issues continue to remain a priority for government and private industry as well. Experts in the physical security industry note that many companies’ failure to remain abreast of new technology adoption opportunities only adds a new wrinkle to long-standing concerns about skilled security personnel recruitment and job conditions that undermine personnel safety and general well-being (https://ibn.fm/pQnqg). Knightscope’s robots have the capability to present companies with automated alternatives to human personnel, overcoming many of the historical problems with security in the process. “One of the more obvious roles for robots in security is that they’re highly productive in repetitive and dangerous tasks,” EVP and Chief Client Officer, Stacy Stephens, states in a company video (https://ibn.fm/ophuT). “So if you can imagine putting a human being into a place where they’re doing the same thing over and over and over again, they become ineffective very, very quickly. You can also imagine having to put somebody in the line of fire in a dangerous situation — a robot doesn’t care about that. You put them in there instead of a human being, you make it safer and much more productive.” The company has used a human resources and recruitment type of model to promote its sentries, developing a resume of sorts that showcases the K5 models’ professional history, successes, capabilities and attributes. The work experience element of its profile notes “the diversity of the K5’s ‘employers’ and the multitude of industries in which Knightscope robots may be utilized,” for example, while the education section highlights the software used in the model (https://ibn.fm/RY8Lp). Among its accomplishments, the robot’s CV lists statistics showing it has helped generate a 46 percent decrease in crime reports since being deployed at the Huntington Park Police Department, as well as a 68 percent decrease in citations but a 27 percent increase in arrests. And the company even lists the K5’s “hobbies,” such as providing evidence for prosecuting criminals, deterring vagrancy and preventing vehicle break-ins. “The goal was to use the K5 resume to apply to job postings looking to hire security guards and, in doing so, getting the information about security robots into the hands of decision makers. The plan worked and we booked several demos within the first week of activity,” Knightscope’s report on the approach states. The K5 is an outdoor model designed for mobility access areas. It is joined by a lineup of K1 stationary machines and roving K3 indoor machines, self-driven by artificial intelligence to maintain its energy level, detect potential problems and record / transmit its interactions while also sustaining interactivity with human operators. Knightscope has the backing of four major corporations and more than 17,000 investors, many of whom are “chief security officers of major corporations … NYPD detectives, (representatives of the) FBI, CIA, (and) DHS,” according to CEO William Santana Li (https://ibn.fm/EizbW). For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• Pure Extracts Technologies recently provided update into its expansion into functional mushrooms sector
• Functional mushrooms have enjoyed surge in popularity as of late, are increasingly being used in wide variety of healthcare, pharmaceutical products
• Functional mushrooms sector is expected to grow to annual market value of $34.4 billion by 2024
• Pure Extracts plans to develop high bio-available products derived from functional mushrooms through use of its proprietary extraction processes
• Company also set to launch its own branded functional mushrooms-based products under ‘Pure Mushrooms’ brand from Q1 2021 onwards and has signed a LOI with the PURICA(TM) brand of mushroom wellness products

Pure Extracts Technologies (CSE: PULL) (XFRA: A2QJAJ), a plant-based extraction company focused on the cannabis, hemp, and functional mushroom sectors, recently updated investors on its expansion into the functional mushroom wellness sector, which have built upon its existing ventures. One such venture, initiated in December, is its extraction tolling business – a process through which cannabis and hemp biomass is converted into THC and CBD oil.

Functional mushrooms can be defined as a modified type of mushroom variety with added benefits relative to traditional mushroom varieties, often boasting extremely high nutritional profiles and possessing a number of medicinal and flavor-enhancing benefits. The sector has enjoyed a remarkable upsurge in popularity as of late, with functional mushrooms increasingly used in a wide variety of healthcare and pharmaceutical products; this in turn has increased the applicability of these mushrooms in the food and beverage sector as well as their use as a functional ingredient incorporated into health supplements.

The rise in popularity of functional mushrooms has been coupled by increased institutional interest in the field of psychedelics in general, with a focus on promising mushroom varieties such as psilocybin specifically – with psilocybin being considered for treatment options including depression, anxiety, PTSD, bipolar disorder, Alzheimer’s disease and addiction.

In fact, a recent study carried out by Mordor Intelligence, which delved deeper into the evolving consumption trends and uses being attributed to the product, forecast that the functional mushroom sector would grow at a CAGR of 8% between 2019 to 2024 (https://ibn.fm/hcHgw), rising to a value of $34.4 billion by the end of 2024.

Pure Extracts, seeking to capitalize on the growing interest within the sector, has expanded its business model to include mushroom formulations using extraction processes which have proven compatible with the Company’s existing infrastructure. Working in conjunction with the Company’s scientific advisor—Dr. Alexander MacGregor, founder of the Toronto Institute of Pharmaceutical Technology—Pure Extracts plans to develop high bio-available products and novel delivery methodologies, which will include tinctures, pills, capsules and edibles.

This experience will be exceptionally valuable to Pure Extracts as it prepares to enter the psychedelic mushroom market, especially given the recent December 8th announcement that 17 healthcare professionals associated with TheraPsil, a non-profit, patient-rights advocacy group, have been approved by the Federal Canadian Health Minister, Patty Hajdu, to possess and use psilocybin for professional training in psilocybin therapy. The approved healthcare professionals include psychologists, psychiatrists, clinical counselors, social workers, general practitioners, and nurses. These approvals were granted through exemptions to section 56(1) of the Canadian Drugs & Substances Act.

Moving further, Pure Extracts will also seek to expand its portfolio of branded functional mushroom-derived products under the ‘Pure Mushrooms’ brand name. The products are believed to boost memory, provide immune system support or reduce stress, and they will be marketed from Q1 2021 onwards via direct-to-consumer sales through Pure Extract’s e-Commerce web portal.

“Moving into the field of mushroom extractions is an obvious and exciting opportunity to leverage our advanced technology and proven capabilities,” commented Pure Extracts CEO Ben Nikolaevsky in regards to the commercial potential of the Company’s expansion into the functional mushroom sector. “We look forward to launching our functional products commercially within the next few months and can’t help but see the similarities to the cannabis sector regarding the pathways to both medical and recreational legalization. I believe our ability to immediately begin working in this burgeoning sector will create immense value for our business, our stakeholders, partners and shareholders alike” (https://ibn.fm/WXmYB).

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• Imagin Medical Inc. is a surgical imaging company building a platform of technological products designed to improve endoscopic surgeries through adaptable equipment that makes it easier to see anomalies such as cancerous tumors
• The company’s initial product launch will focus on bladder cancers visible under blue light thanks to a dye on the market that currently depends on the acquisition of expensive new equipment by hospitals
• Imagin’s proprietary i/Blue Imaging (TM) System resolves some of the expense and flexibility concerns expressed by urologists, which will grant surgeons the capacity to better root out cancers
• Imagin has announced an offering of up to $3 million in aggregate principal in convertible notes, and closed the initial $750,000 tranche last month

Science fiction introduced the world to the concept of the invisible man — a person who could move through society without anyone knowing where he was. Imagin Medical (CSE: IME) (OTCQB: IMEXF) has improved on the trope of science fiction, making it possible to better see the “invisible” interior recesses of men and women during medical procedures so that surgeons can more effectively root out cancers in a minimally invasive manner. Imagin Medical will launch its platform with the introduction of the i/Blue Imaging (TM) System, a proprietary imaging technology based on advanced optics and light sensors. The value of Imagin’s platform is that it makes surgery-revolutionizing technology more available to hospitals by providing it in manner adaptable to the equipment hospitals already own. “One very good technology that has been developed is what’s known as blue light cystoscopy,” Kaiser Permanente urologist Mehrdad Alemozaffar explains in an Imagin webinar on the company’s technology (https://ibn.fm/Y9Qu2). “Cysview is the drug that’s used,” Alemozaffar states. “What’s done with blue light cystoscopy is that the drug is instilled into the bladder just before the patient goes to the operating room and in the operating room a camera … emits a blue light and, essentially, any cancer would have taken up that drug much more rapidly, and under this blue light actually shines back at us a very bright pink color.” The pink definition of the tumor allows surgeons to see the cancer better than if they were looking at it under standard white light. The company’s webinar states that the blue light procedure helps identify 25 percent more tumors but that it is used in less than 10 percent of urological procedures, despite its recommendation by the American Urological Association, in part due to the prohibitive costs of the equipment involved as well as the challenges of switching back and forth between white and blue light systems during the course of the procedure. Imagin’s tech “addresses the limiting factors of current blue light with one easy-to-use integrated system,” the webinar narrator states, by displaying white and blue light images side-by-side simultaneously on the surgeon’s monitor and by providing a device that consolidates the surgical light source, video camera and data recording technology in an implement that is adaptable to almost any scope on the market. “Leading urologists have told us that the ability to see both images at the same time will allow them to efficiently eliminate more cancer cells,” the narrator states. “No matter which standard scopes a hospital owns today, they cannot use blue light with them. Imagin solves this problem with a system-agnostic camera head that will work with almost any standard cystoscope that a hospital already owns.” The company’s initial i/Blue Imaging product is purposed for bladder cancer surgeries, but the company intends to expand its technology for multiple endoscopic medical procedures in the future, including laparoscopic, colorectal and thoracic procedures that use a variety of contrast dye agents and illumination sources. Last month, the company closed the first $750,000 tranche of a proposed investor offering of up to $3 million in aggregate principal (https://ibn.fm/HhVRg) in convertible notes. The notes can be converted to units that will be made up of one post-consolidated common share, a one-half common share purchase warrant exercisable at $0.50 USD and a one-half common share purchase warrant exercisable at $0.60 USD. The notes will accrue 10 percent interest annually, payable semi-annually in arrears; and will mature 18 months following the date of issue, according to the company (https://ibn.fm/LCAFo). For more information, visit the company’s website at www.ImaginMedical.com. NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• Precision medicine is emerging approach to disease prevention, treatment that incorporates individual’s distinctive characteristics.
• New approach allows doctors, researchers to predict more accurately which treatments may work better.
• Helomics’ database, largest of its kind, is comprised of ovarian, head and neck, colon and pancreas tumors.

Science has discovered that thumbprints and DNA aren’t the only biological elements that make individuals unique. In fact, ears, eyes, tongues and even the way a person walks is distinctive, unlike anybody else in the world (https://ibn.fm/SJX27). Moreover, the things that make people different from each other don’t stop at physical characteristics. Predictive Oncology (NASDAQ: POAI) is building a business around precision medicine, an emerging approach to disease prevention and treatment that identifies the variability in genes, environment and lifestyle for each individual, and then uses that information to provide individualized treatments designed to ultimately improve patient outcomes (https://ibn.fm/Va9HX). “This new approach will allow doctors and researchers to predict more accurately which treatment and prevention strategies for a particular disease will work in which groups of people,” explains a MedLinePlus article. “It is in contrast to a one-size-fits-all approach, in which disease treatment and prevention strategies are developed for the average person, with less consideration for the differences between individuals.” POAI realizes that “just genomics” is not enough to deliver personalized therapeutic options. The company believes that a multi-omic approach to disease, or one that gathers data from multiple levels such as genome, epigenome, transcriptome, proteome and metabolome, offers a much greater chance of success. With that in mind, Predictive Oncology is addressing cancer, specifically ovarian cancer, by leveraging the synergies of two of its wholly owned subsidiaries — Helomics and TumorGenesis — to bring precision medicine to the space. One of POAI’s highest priorities is building multi-omic predictive models of tumor drug response and outcome. The company accomplishes this through its subsidiary Helomics and by using its proprietary TumorSpace knowledge base of 150,000 tumor drug response profiles gathered from more than 15 years of clinical testing. “We have developed a unique technology that combines our clinically validated primary tumor cell assay and drug response data . . . together with proven artificial intelligence (AI) to allow us to test potential drugs against patient tumor cells, much earlier in the drug discovery process,” the company explains (https://ibn.fm/GRRXb). “We believe this patient-centric approach will significantly improve the success of translating compounds into the clinic, saving time, cost, and most importantly getting therapies to patients more quickly.” Helomics’ database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. The company’s CLIA-certified lab provides testing that assists oncologists in identifying personalized patient treatment options. TumorGenesis is developing a new approach to growing tumors in the laboratory without the use of rats or mice. This exclusive methodology “fools” the tumor into thinking it is still in the body; therefore, it reacts as it naturally would, increasing the accuracy of the biomarker. These biomarkers are then used in TumorGenesis’ Oncology Capture Technology platforms, which isolate and help categorize an individual patient’s heterogeneous tumor samples. The process provides critical information that can be used to develop patient-specific treatment options. For more information on Predictive Oncology, visit the company’s website at www.Predictive-Oncology.com. NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI